Elevar Therapeutics’ Post

Vividion Therapeutics, Inc. Initiates P-I Trial of VVD-130850 for Treating Advanced Solid and Hematologic Tumors #vividiontherapeutics #vvd130850 #solidtumors #hematologictumors #clinicaltrial #phase1 #safety #efficacy #tolerability #pharmacokinetics #pharmacodynamics #patients

As early investors in Dyne Therapeutics, we are pleased to share they reported positive updates in their next-generation exon skipping program for Duchenne amenable to skipping exon 51. In their phase 1/2 Trial, Dyne-251 at dose of 10 mg/kg given once a month showed an average 3.2% normal dystrophin expression (7.6% normal dystrophin when adjusted for muscle content) at 6 months. Trends in functional improvements like the NSAA and other tests were observed, but non reached statistical significance at this time. Dyne-251 has fully enrolled cohorts for 20 and 40 mg/kg dosing and is reporting favorable safety profiles, while dystrophin and functional read outs for these higher doses will be coming in the future.    Dyne also reported positive safety, biomarker, functional, and patient reported outcome data in Type 1 Myotonic Dystrophy program (DM1), and anticipates providing updates by the end of the year on their plans for pursuing expedited FDA approvals in both DM1 and Duchenne. #FDA #DMD #DUCHENNE #CUREDUCHENNE #CLINICALTRIALS

💫 FDA Approval 💫 🌟 U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors 👉 Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors, demonstrating clinically meaningful response rates in the TRIDENT-1 trial 🔗 https://buff.ly/4cf7pEN #OncEd #ONCOnews #OncoAlert

NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225): Highlights Long term, multi-year supply agreement provides Alpha-9 with NorthStar's high purity non-carrier added (n.c.a.) Ac-225 to be used in Alpha-9's targeted radiopharmaceutical programs for treatment of solid and liquid tumors. Agreement will support Alpha-9's ongoing development...

Obe-cel, an investigational therapy utilizing CD19 CAR T cells, aims to address the limitations in clinical effectiveness and safety observed with existing CD19 CAR T cell treatments. Autolus Therapeutics presents extended follow-up results and further data analysis from the key Phase Ib/II FELIX study of obecabtagene autoleucel (obe-cel) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Benefit from Expert Insights and Extensive Analysis with DelveInsight Business Research LLP's ASCO 2024 Exclusive Coverage! https://lnkd.in/gE3gUFyM #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology. This is the first recorded trial to systematically compare the efficacy, population pharmacokinetics, and safety profile of MW032 and reference denosumab in patients with solid tumors with bone metastasis through a 53-week, multicenter, randomized, double-blind, phase 3 equivalence trial. Read more at: https://lnkd.in/gHErs4bs

Great article from FirstWord with Loxo@Lilly EVP Jacob Van Naarden on their ambitions for targeted radiopharmaceuticals: https://lnkd.in/eR9grXD6 I took away 3 key success factors for a targeted radiopharmaceutical franchise: -Assurance of radionuclide supply (either through manufacturing or supply chain relationships) and contingent upon radionuclide supply and other factors, the ability for manufacturing to meet demand -Radionuclide diversity, both to hedge against supply constraints as well as to address different therapeutic goals (also discussed here: https://lnkd.in/ecDEsU5y) -Breadth of targets / tumor types in the clinical development plan (also discussed in the article mentioned above)

🌟 Latest News Highlights! 🌟 1. 🧪 Reviva Pharmaceuticals secures #EU patent for its innovative pulmonary hypertension drug! 2. 🤝 XyloCor Therapeutics, Inc. partners with SmartCella Holding AB to advance cardiovascular therapies! 3. 👁️ OKYO Pharma makes strides in developing new therapies for dry eye syndrome! 4. 📑 Elevar Therapeutics resubmits NDA for Rivoceranib, aiming to bring new hope to cancer patients! 💬 Join the Conversation! Which news excites you the most? Share your thoughts below! 🗣️ 🔗 Stay tuned for more updates and exclusive content! #PharmaNow #PharmaNews #HealthcareInnovation #Partnerships #MedicalAdvancements #StayTuned

Innovating #ProstateCancer treatment, our latest advancement introduces pre-filled syringes for #Radiopharmaceutical therapies, ensuring precise, safe, and convenient care. This leap towards #PrecisionMedicine highlights our dedication to transforming cancer treatment, focusing on patient-centric approaches. Discover how these developments promise to redefine therapy effectiveness on GRG Online. #HealthInnovation #CancerCareProgress https://lnkd.in/dQGitAGu

Abdera Therapeutics launched in April 2023 with $142M in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals for the treatment of cancer. Today, FDA has cleared its IND for ABD-147, the first precision radiopharmaceutical therapy targeting DLL3 for the treatment of small cell lung cancer and large cell neuroendocrine carcinoma. ABD-147 is a next-generation precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to solid tumors expressing DLL3. DLL3 is a protein found on the surface of neuroendocrine tumors, but rarely expressed on the surface of normal cells or tissues. Trial initiation is expected in the second half of 2024.